7/14/2017

Dolasetron Mesylate Injection

Products Affected - Description

- Anzemet intravenous injection, Validus Pharmaceuticals, 100 mg, 5 mL single dose vial, 1 count, NDC 00088-1206-32
- Anzemet intravenous injection, Validus Pharmaceuticals, 12.5 mg, 0.625 mL single dose vial, 6 count, NDC 00088-1208-06
- Anzemet intravenous injection, Validus Pharmaceuticals, 500 mg, 25 mL multiple dose vial, 1 count, NDC 00088-1209-26

Reason for the Shortage

- Validus Pharmaceuticals acquired Anzemet injection from Sanofi US in December 2015.
- Validus Pharmaceuticals has temporarily discontinued all Anzemet injection presentations and cannot estimate a resupply date.

Estimated Resupply Dates

- Validus Pharmaceuticals has temporarily discontinued all Anzemet injection presentations and the company cannot estimate a resupply date.

Updated

Updated July 14, 2017 by Leslie Jensen, PharmD, Drug Information Specialist. Created February 29, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.